Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U.S. Reborn1 Clinical Trial to Commence
Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U.S. Reborn1 Clinical Trial to Commence OTTAWA, ON / ACCESSWIRE / January 29, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the U.S. Food and Drug Administration (FDA) has cleared the Companys Investigational New Drug (IND) application, allowing Tetra to initiate its QIXLEEF TM Reborn1 TM clinical trial in cancer patient...
Scioli Montoto Pascal Nigen Tetra Bio Pharma Inc Alpha Bronze Company Investigational New Drug Drug Administration
Source: finanznachrichten.de